Atea Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AVIR Nasdaq 2834 ateapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 - Aug 5th, 2026 5:00 am
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data - Jul 29th, 2026 5:00 am
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Jul 29th, 2026 3:45 am
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial - Jul 28th, 2026 6:27 am
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus - Jul 28th, 2026 5:00 am
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - Jul 14th, 2026 5:00 am
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Jun 25th, 2026 5:00 am
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know - Jun 18th, 2026 10:00 am
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Jun 9th, 2026 7:40 am
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 - May 27th, 2026 5:00 am
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks - May 25th, 2026 6:05 am
Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - May 19th, 2026 6:46 am
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround - May 15th, 2026 7:35 am
Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 13th, 2026 6:30 am
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - May 13th, 2026 5:00 am
Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... - May 12th, 2026 11:01 pm
Atea Pharmaceuticals Q1 Earnings Call Highlights - May 12th, 2026 4:08 pm
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - May 12th, 2026 2:05 pm
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 - May 5th, 2026 5:00 am
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Mar 6th, 2026 6:30 am